Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Rating) was the recipient of a large decrease in short interest in May. As of May 31st, there was short interest totalling 48,900 shares, a decrease of 48.4% from the May 15th total of 94,700 shares. Based on an average trading volume of 98,600 shares, the days-to-cover ratio is […]
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) and Rain Oncology (NASDAQ:RAIN – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability. Analyst Ratings This is a breakdown of recent recommendations […]
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Rating) was the recipient of a large decline in short interest in May. As of May 15th, there was short interest totalling 94,700 shares, a decline of 16.0% from the April 30th total of 112,800 shares. Currently, 4.2% of the shares of the stock are sold short. Based on […]